HC Wainwright Reaffirms Buy Rating for Collegium Pharmaceutical (NASDAQ:COLL)

Collegium Pharmaceutical (NASDAQ:COLL)‘s stock had its “buy” rating reaffirmed by investment analysts at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $50.00 price target on the specialty pharmaceutical company’s stock. HC Wainwright’s price target indicates a potential upside of 65.84% from the company’s current price.

Other equities research analysts also recently issued reports about the company. Piper Sandler lowered their price target on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a report on Tuesday, February 4th. Needham & Company LLC upgraded Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $43.60.

Collegium Pharmaceutical Stock Performance

Shares of NASDAQ:COLL opened at $30.15 on Monday. The company has a market capitalization of $949.30 million, a price-to-earnings ratio of 13.00 and a beta of 0.99. The firm’s 50 day simple moving average is $30.57 and its 200 day simple moving average is $32.54. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. Collegium Pharmaceutical has a fifty-two week low of $27.28 and a fifty-two week high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The company had revenue of $181.95 million for the quarter, compared to analyst estimates of $179.68 million. As a group, sell-side analysts forecast that Collegium Pharmaceutical will post 5.62 earnings per share for the current year.

Insider Buying and Selling at Collegium Pharmaceutical

In other news, EVP Shirley R. Kuhlmann sold 40,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at $4,330,048.32. This trade represents a 20.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Colleen Tupper sold 10,445 shares of the business’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $30.01, for a total transaction of $313,454.45. Following the completion of the sale, the chief financial officer now directly owns 165,246 shares in the company, valued at approximately $4,959,032.46. This represents a 5.95 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 109,193 shares of company stock valued at $3,243,594 in the last 90 days. 3.98% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Collegium Pharmaceutical

A number of large investors have recently modified their holdings of the business. Intech Investment Management LLC bought a new stake in Collegium Pharmaceutical during the third quarter worth about $374,000. Massachusetts Financial Services Co. MA increased its position in shares of Collegium Pharmaceutical by 17.9% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 765,692 shares of the specialty pharmaceutical company’s stock worth $29,586,000 after purchasing an additional 116,327 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in shares of Collegium Pharmaceutical by 4.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 381,494 shares of the specialty pharmaceutical company’s stock worth $14,741,000 after purchasing an additional 16,655 shares in the last quarter. Penserra Capital Management LLC acquired a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $757,000. Finally, Advantage Alpha Capital Partners LP acquired a new stake in shares of Collegium Pharmaceutical in the 3rd quarter valued at approximately $341,000.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.